Invest in a Noor-built location
Don't invest in Noor.
Noor Medical Group is a pharmacy developer — we build, license, staff, and launch each sterile compounding pharmacy as a discrete capital project. Each location is its own investment thesis: a specific site, a defined referral network, and a clear strategic exit. Our current open project is Coral Springs.
A $23.6B market growing nearly 10% a year.
The U.S. home infusion market was estimated at $23.6 billion in 2026 and is projected to reach $49.8 billion by 2034 — driven by an aging population, rising chronic disease prevalence, and a systemic shift from inpatient to home-based care. Industry leaders like Option Care Health and KabaFusion demonstrate the scale. Noor Medical Group is built to capture regional demand within this national tailwind.
U.S. home infusion market (2026)
A national market Noor is built to capture region by region.
Projected market by 2034
Nearly 10% annual growth — a compounding tailwind.
Annual market CAGR
Sustained demand from aging, chronically ill populations.
Typical strategic exit horizon
Sale to a national infusion operator or IPO pathway.
We de-risk every phase — then hand you the keys.
Most startup pharmacies fail at customer acquisition and regulatory delay. Noor removes both by building the cleanroom, securing the licenses, recruiting the team, and establishing the referral network before a single patient is treated.
A proven developer model
Noor Medical Group is a pharmacy management organization. We don't just open a pharmacy — we identify the site, engineer the cleanroom, secure the licenses, recruit the clinical team, and stand up the referral network. Each location is a discrete, capital-efficient project.
Local sterile compounding can't be outsourced
TPN, custom antibiotic combinations, and cardiac inotropes are compounded to a single patient's blood values with shelf lives measured in hours. A distant mail-order pharmacy can't respond in time. The medication has to be made locally, the same day — which is exactly what Noor builds.
Day-one referrals, not a cold start
We launch every location with established hospital and specialist relationships already in place — not a months-long ramp. Referrals flow from day one because the network is built before the doors open.
Coral Springs IV Specialty Pharmacy
Flagship Launch · Q1 2027 · Coming soon
Proposed Pre-Money Valuation
U.S. Infusion Market
Facility Security
Strategic Exit Horizon
This is our currently open capital project — a proposed $1.8 million valuation before this round, backed by secured clinical relationships, validated research demand, a signed lease LOI with rent abatement, and a clear 3–5 year strategic exit. Get in while you can.
The foundation is built. Capital completes it.
Research demand
A clinical research center explicitly requested our pharmacy on site — pre-launch demand for study-protocol sterile compounding.
Fixed-price cleanroom
Proposal locked with specialized engineers, eliminating construction cost-overrun risk for USP 797/800.
24-month downside modeling
Stress-tested cash flow projections with conservative ramp-up and working capital contingencies.
Pharmacy counsel oversight
Dedicated health regulatory counsel reviewing every compounding, billing, and payer workflow.
Signed lease LOI
Six months of rent abatement and expansion rights secured at 3080 NW 99th Avenue.
Established referral network
Hospital and specialist relationships already in place across Broward, Boca, Wellington, and West Palm Beach.
The team that runs this location.
Each Noor location is staffed with a defined clinical and operational team — recruited and vetted before launch so patient services start on day one.
- Pharmacist in Charge (PIC): Sterile compounding & USP specialist candidate identified.
- Quality & Sterility Lead: Oversees cleanroom SOPs, environmental testing, batch verification.
- Compounding Technicians: Experienced in aseptic technique and automated compounding devices.
- Specialty Billing Specialists: Dedicated prior-authorization and reimbursement team.
- Temperature-Controlled Couriers: Reliable same-day delivery throughout South Florida.
A 3–5 year path to liquidity.
1. Strategic Acquisition. Preferred exit — acquisition by an established national infusion operator such as Option Care Health or KabaFusion, or a regional health system seeking accredited South Florida sterile compounding capacity.
2. Management Buyout / Redemption. Secondary alternative leveraging strong operational cash flow to redeem investor shares at an attractive multiple.
3. Multi-Site Expansion & IPO. Long-term ambition to replicate this model into top metro areas nationwide.
Coral Springs Flagship · Direct Executive Review
Request the Coral Springs investor memorandum & valuation deck.
Accredited investors and healthcare venture partners can request our full 24-month financial model, lease LOI documentation, and cleanroom engineering specs for the Coral Springs flagship.